
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE reported a 13% year-over-year increase in product sales for 2024, totaling €163.3 million, alongside a total revenue rise of 10% to €169.6 million compared to 2023. The company anticipates that Ixchiq sales will surpass €100 million by the third year of its commercial launch, driven by recent FDA accelerated approval and the anticipated expansion of the chikungunya vaccine market, projected to exceed $500 million annually. Furthermore, Valneva's management asserts the company has sufficient cash reserves to reach critical inflection points, reinforcing a strong financial outlook for future growth.
Bears say
Valneva SE faces a negative outlook primarily due to a substantial reduction in revenue estimates, with the 2025 projection decreased from €222.5 million to €185 million. Additionally, the expectation for 2025 earnings per share (EPS) has been downgraded to (€0.65) from (€0.53), indicating a worsening financial performance. The anticipated sales for the Ixchiq vaccine are also projected to decline significantly, with 2029 sales estimates being reduced to €225 million from €250 million, further compounding the challenges facing the company.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares